Literature DB >> 35798922

Serum alanine aminotransferase level and intravenous immunoglobulin resistance in patients with kawasaki disease.

Hiroya Masuda1, Ryusuke Ae2, Taka-Aki Koshimizu3, Koki Kosami4, Nobuko Makino4, Yuri Matsubara4, Teppei Sasahara4, Yosikazu Nakamura4.   

Abstract

INTRODUCTION/
OBJECTIVES: Serum alanine aminotransferase (ALT) elevation is considered a risk factor for resistance to initial intravenous immunoglobulin (IVIG) treatment in patients with Kawasaki disease (KD). However, serum ALT levels change dramatically during acute KD illness. We tested the hypothesis that risk assessment for initial IVIG resistance based on serum ALT elevation may differ by examination day after KD onset.
METHODS: We analyzed 18,492 population-based patients who developed KD throughout Japan. First, we epidemiologically evaluated the serum ALT variation at 1‒10 days after disease onset. Second, we conducted multivariable logistic regression to determine the association between serum ALT level and initial IVIG resistance according to timing of initial hospital visit by stratifying the patients into an early group (1‒5 days after onset) and a late group (6‒10 days after onset).
RESULTS: Serum ALT rapidly increased after KD onset, peaked at day 4 of illness, and then declined regardless of IVIG responsiveness. The adjusted odds ratio (OR) increased with increasing serum ALT in the early group (adjusted OR [95% CI]: 1.44 [1.25-1.66], 1.94 [1.65-2.28], and 2.22 [1.99-2.48] for serum ALT 50-99, 100-199, and ≥ 200 IU/L, respectively; reference ALT level: 1-49 IU/L). No significant association was observed in the late group.
CONCLUSIONS: The findings indicate that risk assessment for initial IVIG resistance based on serum ALT level may only be reliable for patients with KD who visit hospitals during early illness, specifically 1-5 days after disease onset. Key Points Serum alanine aminotransferase level differed markedly according to examination days after Kawasaki disease onset. Serum alanine aminotransferase level declined toward normal range after day 5 of illness regardless of intravenous immunoglobulin responsiveness. Elevated serum alanine aminotransferase level was no longer a significant risk factor for initial intravenous immunoglobulin resistance when measured on delayed hospital visits. Risk assessment for initial intravenous immunoglobulin resistance based on serum alanine aminotransferase level may only be reliable for patients who visit hospitals during early illness, specifically 1-5 days after disease onset.
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Intravenous immunoglobulin; Kawasaki disease; Serum alanine aminotransferase

Mesh:

Substances:

Year:  2022        PMID: 35798922     DOI: 10.1007/s10067-022-06278-w

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  39 in total

1.  Initial intravenous gammaglobulin treatment failure in Kawasaki disease.

Authors:  C A Wallace; J W French; S J Kahn; D D Sherry
Journal:  Pediatrics       Date:  2000-06       Impact factor: 7.124

2.  Cardiac transplantation for giant coronary artery aneurysms complicating Kawasaki disease.

Authors:  J M Travaline; S M Hamilton; R E Ringel; J C Laschinger; A A Ziskind
Journal:  Am J Cardiol       Date:  1991-08-15       Impact factor: 2.778

3.  Outcomes in Kawasaki disease patients with coronary artery abnormalities at admission.

Authors:  Ryusuke Ae; Joseph Y Abrams; Ryan A Maddox; Lawrence B Schonberger; Yosikazu Nakamura; Masanari Kuwabara; Nobuko Makino; Yuri Matsubara; Daisuke Matsubara; Koki Kosami; Teppei Sasahara; Ermias D Belay
Journal:  Am Heart J       Date:  2020-05-03       Impact factor: 4.749

4.  The treatment of Kawasaki syndrome with intravenous gamma globulin.

Authors:  J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

5.  Epidemiology, Treatments, and Cardiac Complications in Patients with Kawasaki Disease: The Nationwide Survey in Japan, 2017-2018.

Authors:  Ryusuke Ae; Nobuko Makino; Koki Kosami; Masanari Kuwabara; Yuri Matsubara; Yosikazu Nakamura
Journal:  J Pediatr       Date:  2020-05-23       Impact factor: 4.406

Review 6.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.

Authors:  Brian W McCrindle; Anne H Rowley; Jane W Newburger; Jane C Burns; Anne F Bolger; Michael Gewitz; Annette L Baker; Mary Anne Jackson; Masato Takahashi; Pinak B Shah; Tohru Kobayashi; Mei-Hwan Wu; Tsutomu T Saji; Elfriede Pahl
Journal:  Circulation       Date:  2017-03-29       Impact factor: 29.690

7.  Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group.

Authors:  J C Burns; E V Capparelli; J A Brown; J W Newburger; M P Glode
Journal:  Pediatr Infect Dis J       Date:  1998-12       Impact factor: 2.129

Review 8.  Kawasaki syndrome.

Authors:  Jane C Burns; Mary P Glodé
Journal:  Lancet       Date:  2004 Aug 7-13       Impact factor: 79.321

9.  High-dose intravenous gammaglobulin for Kawasaki disease.

Authors:  K Furusho; T Kamiya; H Nakano; N Kiyosawa; K Shinomiya; T Hayashidera; T Tamura; O Hirose; Y Manabe; T Yokoyama
Journal:  Lancet       Date:  1984-11-10       Impact factor: 79.321

10.  Serum sodium level associated with coronary artery lesions in patients with Kawasaki disease.

Authors:  Hiroya Masuda; Ryusuke Ae; Taka-Aki Koshimizu; Masami Matsumura; Koki Kosami; Kanako Hayashida; Nobuko Makino; Yuri Matsubara; Teppei Sasahara; Yosikazu Nakamura
Journal:  Clin Rheumatol       Date:  2021-08-07       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.